Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05855083 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
A Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies, sponsored by Omeros Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 16
- Study locations
NCT05855083: Recruiting Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies, sponsored by Omeros Corporation.
NCT05855083 is a Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies that is actively recruiting participants, run by Omeros Corporation. The registered enrollment target is 18 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 16 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05855083, a Phase 2 study of Hematopoietic Stem Cell Transplantation and Thrombotic Microangiopathies, is actively recruiting participants, sponsored by Omeros Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Primary Outcome
Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA
Conditions Studied
Interventions
- DRUG Biological: narsoplimab
Study Locations (16)
Other
- Omeros Investigational Site - Halle
- Omeros Investigational Site - Hanover
- Omeros Investigational Site - Haifa
- Omeros Investigational Site - Jerusalem
- Omeros Investigational Site - Ramat Gan
- Omeros Investigational Site - Tel Aviv
- Omeros Investigational Site - Utrecht
- Omeros Investigational Site - Pamplona
New York
- Omeros Investigational Site - New York
- Omeros Investigational Site - Valhalla
California
- Omeros Investigational Site - San Diego
Florida
- Omeros Investigational Site - Gainesville
Massachusetts
- Omeros Investigational Site - Boston
Missouri
- Omeros Investigational Site - St Louis
Texas
- Omeros Investigational Site - Houston
Washington
- Omeros Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT05855083 shows while recruiting
NCT05855083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Biological: narsoplimab is the first listed.
NCT05855083 lists 16 locations in 8 states (Other, New York, California).
Frequently Asked Questions
What is clinical trial NCT05855083 about?
NCT05855083 is a clinical study titled "Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA". The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
What is the current status of trial NCT05855083?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2023-05-01. Estimated completion is 2025-12.
What conditions does trial NCT05855083 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation, Thrombotic Microangiopathies.
What interventions are being tested in trial NCT05855083?
The interventions under investigation include: Biological: narsoplimab (DRUG).
Who is sponsoring clinical trial NCT05855083?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05855083 being conducted?
This trial has 16 study locations across California, Florida, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05855083's enrollment target sits among peer trials
18 26th of 26 the lowest of 26 other Hematopoietic Stem Cell Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic Stem Cell Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
RECRUITING · Phase 2
-
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
RECRUITING · Phase 2
-
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
-
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
COMPLETED · Phase 2
-
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
COMPLETED · Phase 2
-
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI